Mammary Cell News Volume 6.31 | Aug 14 2014

NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin-Aromatase Interactions
Researchers conducted in vitro studies that utilized sera from obese and normal-weight patients with breast cancer. Conditioned media (CM) from macrophage/preadipocyte cocultures exposed to sera from obese patients stimulated greater breast cancer cell estrogen receptor α activity, proliferation, and migration compared with sera from normal-weight patients, and these differences were eliminated or reduced by the addition of an aromatase inhibitor during CM generation. [Cancer Res] Abstract | Press Release

Oncogenic Suppression of Apoptosis Uncovers a Rac1/JNK Proliferation Pathway Activated by Loss of Par3
Scientists show that loss of Par3 in mammary epithelial cells promotes apoptosis, and that oncogenic Notch overcomes the apoptotic signal to reveal an unexpected pro-proliferative role for loss of Par3 in mammary tumors. [Oncogene] Abstract

Geranylgeranylation Signals to the Hippo Pathway for Breast Cancer Cell Proliferation and Migration
Previous studies have shown that geranylgeranylation (GGylation) is essential for cell survival in many types of cancer. Investigators show that the Hippo pathway mediates GGylation-dependent cell proliferation and migration in breast cancer cells. [Oncogene] Abstract

Modeling Luminal Breast Cancer Heterogeneity: Combination Therapy to Suppress a Hormone Receptor-Negative, Cytokeratin 5-Positive Subpopulation in Luminal Disease
To address the relationships between estrogen (ER)⁺ progesterone (PR)⁺ cytokine 5 (CK5)^– and ER^–PR^–CK5⁺ cells in Luminal cancers and tightly control their ratios scientists generated isogenic pure Luminal and pure Luminobasal cells from the same parental Luminal human breast cancer cell line. [Breast Cancer Res]
Abstract | Full Article

Impaired Cell Death and Mammary Gland Involution in the Absence of Dock1 and Rac1 Signaling
Researchers generated two mouse models with conditional inactivation of dedicator of cytokinesis 1 (Dock1) and ras-related C3 botulinum toxin substrate 1 (Rac1) and revealed that the expression of these genes is not essential in the mammary gland during puberty, pregnancy and lactation. [Cell Death Dis] Full Article

Fascin Is Involved in the Chemotherapeutic Resistance of Breast Cancer Cells Predominantly via the PI3K/Akt Pathway
Scientists previously reported the actin-bundling protein (fascin) as a major regulator of breast cancer metastasis and survival. Molecular and cellular assays were used to gain in-depth understanding of the relationship between fascin and chemoresistance. [Br J Cancer] Full Article

Chk1 Inhibition as a Novel Therapeutic Strategy for Treating Triple-Negative Breast and Ovarian Cancers
Investigators describe the cellular effects of the pharmacological inhibition of the checkpoint kinase Chk1 by the novel inhibitor V158411 in triple-negative breast cancer and ovarian cancer. [BMC Cancer] Abstract | Full Article

CLINICAL RESEARCH

TNF Inhibitor Therapy and Risk of Breast Cancer Recurrence in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Researchers investigate the risk of breast cancer recurrence in rheumatoid arthritis (RA)-patients with tumor necrosis factor (TNF) inhibitor treatment and a history of breast cancer, taking several breast cancer, comorbidity and RA-related prognostic factors into account. [Ann Rheum Dis] Abstract

Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer
Observational studies have suggested a possible protective effect of bisphosphonates on breast cancer, but the effect of bisphosphonate use on risk of breast cancer has not been tested in randomized trials. Investigators assessed the relationship of postmenopausal breast cancer incidence and bisphosphonate use using data from two randomized (1:1), double-blind, placebo-controlled trials. [JAMA Intern Med] Abstract | Press Release

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

MicroVAX Cancer Vaccine First in Human Clinical Trial in Singapore
MicroVAX, LLC announced the commencement of a Phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the breast, prostate, colon, ovary and lung, which have relapsed after initial salvage therapy. [MicroVax, LLC (Vocus PRW Holdings, LLC)] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Research Fellow – Cell Cycle Regulatory Pathways in Breast Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Fellow – Breast Cancer Metastasis (University of Texas MD Anderson Cancer Center)

Postdoctoral Position – Triple Negative Breast Cancer (Weizmann Institute of Science)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Mammary Differentiation (University of British Columbia)

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.